Stock RAPT RAPT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Real-time Estimate Cboe BZX
Other stock markets
 20:40:25 02/05/2024 BST 		5-day change 1st Jan Change
8.09 USD -1.10% Intraday chart for RAPT Therapeutics, Inc. +4.10% -67.32%
04-09 RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients CI
03-27 JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
GL
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
AQ
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
CI
JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating
MT
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
PR
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GL
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
GL
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
PR
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
North American Morning Briefing : S&P 500 Futures -2-
DJ
RAPT Therapeutics Shares Decline Following UBS Downgrade
MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61
MT
North American Morning Briefing : Nvidia Ignites -2-
DJ
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating
MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10
MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RAPT Stock
  4. News RAPT Therapeutics, Inc.